These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 22261737

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial.
    Dakin HA, Wordsworth S, Rogers CA, Abangma G, Raftery J, Harding SP, Lotery AJ, Downes SM, Chakravarthy U, Reeves BC, IVAN Study Investigators.
    BMJ Open; 2014 Jul 29; 4(7):e005094. PubMed ID: 25079928
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Avastin is as effective as Lucentis for wet AMD and could save NHS 84m pound a year, study shows.
    Hawkes N.
    BMJ; 2012 May 09; 344():e3275. PubMed ID: 22573655
    [No Abstract] [Full Text] [Related]

  • 11. [Economic evaluation of bevacizumab versus ranibizumab in neovascular age-related macular degeneration].
    Li H, Li X, Xie F.
    Zhonghua Yan Ke Za Zhi; 2014 Jun 09; 50(6):426-33. PubMed ID: 25241975
    [Abstract] [Full Text] [Related]

  • 12. Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model.
    Patel JJ, Mendes MA, Bounthavong M, Christopher ML, Boggie D, Morreale AP.
    J Eval Clin Pract; 2012 Apr 09; 18(2):247-55. PubMed ID: 20846318
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Three-year safety and visual acuity results of epimacular 90 strontium/90 yttrium brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration.
    Avila MP, Farah ME, Santos A, Carla L, Fuji G, Rossi J, Nau J.
    Retina; 2012 Jan 09; 32(1):10-8. PubMed ID: 21817963
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A Cost-Benefit Analysis of VEGF-Inhibitor Therapy for Neovascular Age-Related Macular Degeneration in the United States.
    Brown GC, Brown MM, Rapuano SB, Boyer D.
    Am J Ophthalmol; 2021 Mar 09; 223():405-429. PubMed ID: 32681907
    [Abstract] [Full Text] [Related]

  • 17. Anti vascular endothelial growth factor sequential therapy for neovascular age-related macular degeneration: is this the new deal?
    Neri P, Mariotti C, Arapi I, Bambini E, Giovannini A.
    Curr Med Res Opin; 2012 Mar 09; 28(3):395-400. PubMed ID: 22283373
    [Abstract] [Full Text] [Related]

  • 18. Avastin is as effective as Lucentis in treating wet age related macular degeneration, study finds.
    Torjesen I.
    BMJ; 2013 Jul 23; 347():f4678. PubMed ID: 23881948
    [No Abstract] [Full Text] [Related]

  • 19. Ranibizumab for age-related macular degeneration: a meta-analysis of dose effects and comparison with no anti-VEGF treatment and bevacizumab.
    Jiang S, Park C, Barner JC.
    J Clin Pharm Ther; 2014 Jun 23; 39(3):234-9. PubMed ID: 24635444
    [Abstract] [Full Text] [Related]

  • 20. Bevacizumab versus ranibizumab: why are we not playing the joker?
    Banfi R, Attanasio F, Palazzi N, Colombini S, Falai T, Cecchi M, Virgili G.
    Int J Clin Pharm; 2013 Aug 23; 35(4):507-9. PubMed ID: 23625322
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.